[CAS NO. 1599441-71-0] Super-TDU
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1599441-71-0]
Store
Catalog
SLK-S8554
Brand
Selleck
CAS
1599441-71-0
DESCRIPTION [1599441-71-0]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 5279.94 |
| Molecular Formula | C237H370N66O69S |
| SMILES | - |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.1894 mL | 0.9470 mL | 1.8940 mL |
| 5 mM | 0.0379 mL | 0.1894 mL | 0.3788 mL |
| 10 mM | 0.0189 mL | 0.0947 mL | 0.1894 mL |
| 50 mM | - | - | - |
Description
Super-TDU is an inhibitory peptide targeting .
Targets
| YAP/TEAD interaction [1] |
In vitro
Super-TDU reduced endogenous interaction between YAP and TEADs. It inhibits cell viability and colony formation of GC cell lines MGC-803, BGC-823, and HGC27, but not MKN-45. Moreover, the Super-TDU downregulated expression of YAP-TEADs target genes CTGF, CYR61, and CDX2. Super-TDU significantly inhibited growth of HeLa, MGC-803, HCT116, A549, and MCF-7 cells, but only marginally inhibited growth of Jurkat and Raji cells, indicating a selectivity of the Super-TDU in inhibiting tumor cell growth. Super-TDU may specifically target tumor cells with an elevated YAP/VGLL4 ratio.
In vivo
Super-TDU has the potential in treating gastric cancer by directly targeting YAP-TEADs, and importantly, unlike the conventional drug compound 5-FU, its antitumor activity tends to be specific toward tumors with an elevated ratio of YAP to VGLL4.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.